Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_assertion type Assertion NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_head.
- NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_provenance.
- NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_assertion evidence source_evidence_literature NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_provenance.
- NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_assertion SIO_000772 25468140 NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_provenance.
- NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_assertion wasDerivedFrom befree-2016 NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_provenance.
- NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_assertion wasGeneratedBy ECO_0000203 NP1244206.RA3CvxNvHm1ag5fZWlaiYagGblh01OYoV46WKmI3keFDU130_provenance.